Key Points for VVOS Investors Vivos expects the full effect of its cost reductions to take hold in the fourth quarter of 2026, with additional…
September 29, 2026
Key Points Adlai Nortye dosed the first patient in Australia in a global Phase 1 trial of AN4035. The U.S. FDA cleared the company’s IND…
August 17, 2026
Femasys Bolsters Its Growth Plan With $30 Million Financing as FemBloc and FemaSeed Programs Advance
Key Points Femasys completed a $30 million private placement after June 30, with up to $60 million in potential additional proceeds if related warrants are…
bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing…
July 22, 2026
Jaguar Health’s Crofelemer Gets Another Compassionate-Use Win in a Tiny but Critical Rare Disease Market
Jaguar Health is expanding the real‑world use of crofelemer, with another infant in the European Union set to receive the drug through compassionate use for…
July 20, 2026
Women’s Oncology Is Entering Its Next Growth Phase as Investment Moves Beyond Breast Cancer
A new PwC report projects the women’s oncology market could approach $110 billion by 2030. Public companies are already advancing innovation across diagnostics, targeted therapies…
BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS have highlighted new preclinical data suggesting that their drug candidate GLIX1 may significantly boost the effectiveness of PARP…
July 17, 2026
Illuccix Japan Study Hits Full Enrollment as Telix Moves Closer to Prostate Cancer Imaging Approval
Telix Pharmaceuticals (NASDAQ: TLX) has hit a key clinical milestone, finishing patient enrollment in its Phase 3 Illuccix Japan study of TLX591‑Px for prostate cancer…
Telix Pharmaceuticals (NASDAQ: $TLX) and St Vincent’s Hospital have started dosing the first patients in OPTIMAL‑e, a clinical trial bringing their next‑generation PSMA‑targeted radioligand therapy…
Fractyl Health Inc. (NASDAQ: GUTS) is highlighting new REMAIN‑1 data that suggest its Revita procedure may help people maintain much of their weight loss for…
Glioblastoma Awareness Day 2026 lands under the theme “Honoring Every Story, Advancing Every Hope.” Four companies are testing immune-based approaches against the disease, each carrying…
Northwest Biotherapeutics Inc. (OTCQB: NWBO) is highlighting updated survival data from its Phase III trial of DCVax-L in glioblastoma that underline a key point: more…